Syntegra

San Francisco, CA All United States companies → — Founded 2019

Clinical AI Platform Developer Platform / API Healthcare Analytics / BI

Laboratory Medicine Pathology Radiology

Developer Tools & APIs Legal, Compliance & Security

Seed Round — $5.625 million

Website Claim this company

Products

Syntegra Synthetic Data

Syntegra

Developer Tools & APIs

Syntegra provided a generative AI platform for healthcare, creating privacy-preserving, statistically representative synthetic datasets for AI model training, research, and product development. The company was reported as 'Out of Business' as of October 2023.

Not available (company out of business)

See all 1 product →

About Syntegra

Syntegra was a healthcare AI company that specialized in generating high-fidelity, privacy-preserved synthetic health data. The company leveraged advanced generative AI, specifically transformer-based language models, through its proprietary algorithm known as the ‘Syntegra Medical Mind’. This technology was designed to learn the underlying statistical patterns of real patient data to create ‘realistic but not real’ synthetic datasets. The primary goal was to unlock the potential of healthcare data by increasing its utility and accessibility, while rigorously protecting patient privacy, often surpassing HIPAA and GDPR standards.

For physicians and healthcare organizations, Syntegra’s synthetic data offered a solution to the long-standing challenge of sharing and accessing sensitive patient-level information. By providing data that maintained the statistical accuracy and intricate relationships of real data without containing any identifiable patient information, Syntegra aimed to streamline data sharing for various purposes. These included accelerating AI/ML model development, facilitating advanced analyses, gaining deeper insights, and improving clinical outcomes. The platform enabled easier and safer data exchange for health systems, life sciences companies, payers, and digital health innovators, thereby fostering innovation in patient care and drug development.

Focus Areas

Synthetic healthcare data generation privacy-preserving AI real-world evidence clinical research analytics AI model development accelerating diagnosis for rare diseases life sciences data access data bias correction missing data imputation

Business Intelligence

Key Investors	Sweat Equity Ventures, Hike Ventures, Innovation Global Capital, Wisconn Valley Ventures, Village Global, Impact Venture Capital, GRIDS Capital, Berkeley Catalyst Fund, Launchpad Capital, Vastly Valuable Ventures, First Spark Ventures
Partnerships	TMA Precision Health, Institute for Health Metrics (IHM), InterGen Data, Datavant, US National Institutes of Health (NIH), Atropos Health
Acquisitions	Out of Business as of Oct 23, 2023
Technology	Syntegra Medical Mind (proprietary synthetic data engine), transformer-based generative model, leveraging transformer-based language models (e.g., GPT-2, GPT-3)

What Physicians Need to Know

Synthetic Healthcare Data Generation

Syntegra specializes in creating 'realistic but not real' patient-level synthetic data that accurately mirrors the statistical properties and patterns of original healthcare data, including EHR, claims, and genomics. This data can include detailed temporal sequences of medical events.

Privacy-Preserving AI

Their core offering, the Syntegra Medical Mind, leverages generative deep learning models (specifically transformer-based language models) to ensure patient privacy beyond HIPAA and GDPR compliance by eliminating re-identification risks.

Real-World Evidence (RWE) & Clinical Research

Syntegra accelerates RWE research, health economics outcomes research (HEOR), and clinical trial design by providing high-fidelity synthetic data. This enables improved trial design, external control arms, population exploration, and in silico trials, facilitating faster feasibility analyses.

AI Model Development & Analytics

They provide privacy-guaranteed data crucial for building predictive models, conducting statistical analyses, generating reports, and training/testing AI/ML models. This reduces development costs and risks, allowing for iteration in non-HIPAA environments.

Accelerating Diagnosis for Rare Diseases

Syntegra's engine is uniquely capable of retaining small cohorts, which are vital for rare disease research. It allows access to synthetic datasets that accurately represent larger populations of patients with rare disorders, enhancing understanding of disease trajectories and treatment responses.

Life Sciences Data Access

They enable seamless and secure sharing of privacy-guaranteed healthcare information, both internally and externally, effectively overcoming strict data privacy regulations like GDPR for accessing European data.

Data Quality Enhancement (Bias & Missing Data)

Syntegra's technology can correct data bias and impute missing values, ensuring the resulting synthetic datasets are fit for purpose and represent a significant improvement in quality for real-world data applications. This aids in designing equitable treatment plans.

Physician Tip

For physicians, Syntegra offers a powerful tool to advance medical knowledge and patient care. Leverage their synthetic data for research and educational purposes, especially when studying rare conditions or developing new AI-driven diagnostic and treatment tools. The privacy-preserving nature of the data means you can explore complex clinical questions and test hypotheses without the extensive regulatory hurdles associated with real patient data. Consider how this can accelerate your understanding of disease patterns, improve the fairness of AI models, and ultimately lead to more personalized and effective patient care.

Syntegra's solutions are designed for seamless integration. They offer a Synthetic Data API for direct access to patient-level data. Furthermore, Syntegra actively partners with other healthcare technology providers, such as Datavant and Atropos Health, to expand data exchange capabilities and integrate with real-world evidence platforms. Their synthetic data can also be integrated with Electronic Health Record (EHR) systems for various clinical and administrative applications.

At a glance

Founded 2019

HQ San Francisco, CA · United States

Team size Reported as 10 employees as of 2024 and 5 employees as of March 31, 2026 during its operational period. However, it is important to note that Syntegra was reported as 'Out of Business' as of October 23, 2023.

CEO Michael D. Lesh, SM MD FACC

Funding Seed Round — $5.625 million

Products 1

Visit site

Products by Syntegra

1 product in the directory

Syntegra Synthetic Data

Syntegra

Developer Tools & APIs

Not available (company out of business)

What the Web Says

Syntegra (syntegra.io) was a company focused on generating privacy-preserved synthetic healthcare data using generative AI, specifically transformer-based language models. The company aimed to address challenges in healthcare data access and sharing, enabling innovation in patient care and accelerating AI/ML model development. However, according to PitchBook, Syntegra was listed as 'Out of Business' as of October 23, 2023.

Overall: Mixed

Strengths

Enabled access to privacy-guaranteed healthcare information, surpassing HIPAA and GDPR standards.
Maintained high statistical fidelity of real data, including rare cohorts and outliers.
Accelerated AI/ML model development and advanced analyses.
Facilitated data sharing without complex compliance and contractual structures.
Pioneered the use of transformer-based language models for synthetic healthcare data.
Offered the ability to augment original data by expanding cohorts, balancing biased populations, and imputing missingness.

Limitations

The company is listed as 'Out of Business' as of October 23, 2023.
Synthetic data may not be truly identical to real data, potentially leading to models struggling with real-world quirks.
Bias present in original data can be carried over into synthetic versions.
Generating high-quality synthetic data requires significant tools, computational power, and expertise.
Some experts suggest synthetic data is best for testing and refinement rather than discovering fundamentally new insights or replacing real data entirely for training production models.
No specific employer reviews for Syntegra (syntegra.io) were found on platforms like Glassdoor or Reddit, likely due to its inactive status.

Based on reviews from: PitchBook, Hospitalogy, AWS Startups Blog, Datarade, PRNewswire, Reddit

Last updated: 2026-05-12

Videos

News, demos, and interviews about Syntegra.

Loading videos...

Videos load interactively. If none appear, search YouTube for Syntegra →

View all on YouTube

Press & Coverage

Alison Doughty PhD (Medium)

Synthetic Health Data: AI Research Without Privacy Risk

This article highlights how synthetic health data, generated by companies like Syntegra, enables AI research and drug development without compromising patient privacy, citing Syntegra's work with NIH and the Bill and Melinda Gates Foundation.

2026-01

PR Newswire

Syntegra Pushes the Boundaries of Generative AI in Healthcare with Recent Tech Updates

Syntegra announced the launch of Syntegra Medical Mind 2.0, an advancement in generative AI technology for creating high-fidelity, privacy-guaranteed synthetic healthcare data.

2022-11

Syntegra (Medium)

Generative AI for Healthcare

This post from Syntegra discusses how generative AI is making a significant impact and has the potential to transform the healthcare industry.

2022-11

PR Newswire

Syntegra Partners with InterGen Data to Provide a Safe Way of Leveraging Healthcare Records to Predict Life Events

Syntegra announced a partnership with InterGen Data to use its synthetic data to help improve individuals' planning and wellbeing by safely leveraging healthcare records.

2022-10

Hospitalogy

Syntegra and Synthetic Data: Solving Healthcare's Data Problem

This article explores how Syntegra is addressing the long-standing challenge of healthcare data access through its synthetic data solutions, aiming to accelerate innovation in care delivery and drug development.

2022-09

Syntegra (Medium)

Synthetic Data, Real-World Evidence and EU Data Protection (GDPR): A Q&A with Sebastian Kloss fromu2026

Syntegra discusses its work with Janssen to generate high-fidelity synthetic data, focusing on real-world evidence and compliance with EU data protection regulations like GDPR.

2022-09

The SaaS News

Syntegra Raises $5.625 Million in Seed Round

Syntegra, a San Francisco-based leader in synthetic healthcare data generation, closed its seed financing round, raising a total of $5.625 million to commercialize its solutions.

2022-01

Syntegra (Medium)

Syntegra: Democratizing Healthcare Data to Accelerate How Treatments Reach Patients

This article outlines Syntegra's mission to democratize healthcare data access through synthetic data, enabling faster innovation in medicine while protecting patient privacy.

2021-09

Frequently Asked Questions

How does Syntegra ensure patient privacy while generating synthetic healthcare data that remains clinically useful for research and development?

Syntegra's platform generates statistically representative synthetic data that mirrors the patterns and relationships of real patient data, but without containing any actual patient identifiers. This process ensures strict privacy compliance, such as HIPAA and GDPR, while providing high-fidelity data suitable for various analytical and AI development tasks.

Can Syntegra's synthetic data accelerate our clinical research initiatives and the generation of real-world evidence (RWE)?

Yes, by providing immediate access to privacy-compliant, large-scale synthetic datasets, Syntegra can significantly reduce the time and cost associated with data access and regulatory approvals for clinical research and RWE studies. This enables faster hypothesis testing, cohort identification, and model validation.

How can Syntegra's synthetic data enhance our healthcare analytics and the development of new AI models?

Syntegra's synthetic data offers a robust resource for training, testing, and validating AI models and analytical tools without exposing sensitive patient information. It provides diverse and scalable datasets, allowing for iterative model development, performance benchmarking, and the exploration of new insights.

How can Syntegra's technology specifically contribute to accelerating the diagnosis of rare diseases?

For rare diseases, where real patient data is often scarce, Syntegra can generate synthetic data that augments existing limited datasets, enabling more robust research and the development of AI models for earlier and more accurate diagnosis. This helps overcome data scarcity challenges that hinder progress in this critical area.

How does Syntegra address common data quality issues, such as bias and missing information, when generating synthetic healthcare data?

Syntegra's advanced algorithms are designed to learn and replicate the underlying statistical distributions of the original data, including patterns of missingness and potential biases. The platform can be configured to correct for identified biases or impute missing data in a statistically sound manner, improving the utility of the synthetic output.

What specific products or services does Syntegra offer, and how do you ensure compliance and provide ongoing support for healthcare organizations?

Syntegra typically offers a platform or API for generating synthetic data, often tailored for specific use cases in research, development, and analytics. The company prioritizes compliance with global healthcare data regulations (e.g., HIPAA, GDPR) and provides dedicated technical support, training, and expert guidance to ensure successful implementation and ongoing utility for its clients.

What is Syntegra's typical pricing model, and what kind of partnerships or collaborations do you engage in within the healthcare ecosystem?

Pricing models for synthetic data solutions often vary based on data volume, complexity, and specific use cases, typically involving subscription or usage-based fees. Syntegra actively seeks partnerships with academic institutions, pharmaceutical companies, healthcare providers, and technology vendors to foster innovation and expand the application of synthetic data across the life sciences and healthcare sectors.

Related Companies

Suggest an Edit →